Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy

3 4

5

7

8

1

2

Jessica Torres Soto¹, J. Weston Hughes², Pablo Amador Sanchez³, Marco Perez³, David Ouyang^{4,5}, Euan Ashley³

- 6 1. Department of Biomedical Data Science, Stanford University
 - 2. Department of Computer Science, Stanford University
 - 3. Department of Medicine, Division of Cardiology, Stanford University
- 9 4. Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center
- Division of Artificial Intelligence in Medicine, Department of Medicine, Cedars-Sinai
 Medical Center
- 12

13 Correspondence: euan@stanford.edu

14 Abstract

15 Determining the etiology of left ventricular hypertrophy (LVH) can be challenging due to the 16 similarity in clinical presentation and cardiac morphological features of diverse causes of 17 disease. In particular, distinguishing individuals with hypertrophic cardiomyopathy (HCM) from 18 the much larger set of individuals with manifest or occult hypertension (HTN) is of major 19 importance for family screening and the prevention of sudden death. We hypothesized that deep 20 learning based joint interpretation of 12 lead electrocardiograms and echocardiogram videos 21 could augment physician interpretation. We chose not to train on proximate data labels such as 22 physician over-reads of ECGs or echocardiograms but instead took advantage of electronic 23 health record derived clinical blood pressure measurements and diagnostic consensus (often 24 including molecular testing) among physicians in an HCM center of excellence. Using over 25 18,000 combined instances of electrocardiograms and echocardiograms from 2,728 patients, we 26 developed LVH-Fusion. On held-out test data, LVH-Fusion achieved an F1-score of 0.71 in 27 predicting HCM, and 0.96 in predicting HTN. In head-to-head comparison with human readers 28 LVH-Fusion had higher sensitivity and specificity rates than its human counterparts. Finally, we 29 use explainability techniques to investigate local and global features that positively and 30 negatively impact LVH-Fusion prediction estimates providing confirmation from unsupervised

31 analysis the diagnostic power of lateral T wave inversion on the ECG and proximal septal

32 hypertrophy on the echocardiogram for HCM. In conclusion, these results show that deep

33 learning can provide effective physician augmentation in the face of a common diagnostic

34 dilemma with far reaching implications for the prevention of sudden cardiac death.

35

36 Introduction

37

38 Hypertrophic cardiomyopathy (HCM) is the most common cardiac genetic disease with an estimated prevalence in the general population of 1:500 to 1:200.¹ HCM is an autosomal 39 40 dominant mendelian disease that can be associated with significant morbidity in the form of heart failure and sudden death.² Thus, identifying patients with HCM has significance well beyond the 41 42 individual, with many proband diagnoses leading to screening of several generations of a family. Diagnosis of HCM can be difficult due to the high prevalence of manifest hypertension in the 43 general population, present in up to 45% of US adults³ (this before counting the occult disease). 44 45 Thus, a common diagnostic dilemma for clinicians when faced with LVH on the ECG or 46 echocardiogram is how to rule out HCM. In a small study, the rates of misclassification of HCM 47 were as high as 30% percent with hypertension being the most common misdiagnosis⁴. Although 48 the American Heart Association provides guidelines for the diagnosis of hypertension and HCM 49 separately, distinguishing between them is a task that most physicians feel ill equipped to 50 perform (understandably as HCM is a rare disease not commonly encountered even in general 51 cardiology practice). This provides an opportunity for physician augmentation through artificial 52 intelligence (AI).

53

New advances in artificial intelligence have led to rapid expansion of medical deep learning applications with an emphasis on medical specialties that hold a high degree of visual pattern recognition tasks like radiology, pathology, ophthalmology, dermatology and most notably cardiology.⁵ Imaging and electrical phenotypes of hypertrophic cardiomyopathy ^{6,7} are the first line clinical tools.

Interpretation of the ECG relies on direct visual assessment making it ideal for deep learning approaches. Previous work has demonstrated that demographic and medical data can be learned including detection of low ejection fraction, something typically requiring echocardiography to confirm ⁸⁻¹¹. Our prior work using video computation of echocardiograms has demonstrated efficient detection of left ventricular hypertrophy and the identification of a broad range of cardiovascular disease.^{12,13}

66

Combining data sources as human diagnosticians do, has the potential to provide an artificial 67 intelligence (AI) algorithm with greater diagnostic power¹⁴. We focus here on the two most 68 69 frequent diagnostic modalities in cardiology. To date, no published work has explored the 70 benefits of a multimodal deep learning model using electrocardiogram and echocardiogram data, 71 although there has been some exploration of combining separately trained diagnostic models in a single pipeline¹⁵. We hypothesize that multimodal deep learning may provide added benefit in 72 73 distinguishing patterns that are not easily discernible from individual modalities. We present 74 LVH-fusion, the first model to jointly model electrical and ultrasound-based time series data of 75 the heart. We demonstrate its potential with application to the diagnosis of left ventricular 76 hypertrophy.

77 Results

78 We developed a multi-modal deep learning framework, LVH-fusion, that takes as input time based 79 electrical and echocardiographic data of the heart. We applied this framework in a common clinical 80 challenge: the determination of the etiology of left ventricular hypertrophy. Motivated by prior work on deep learning applied to electrocardiogram signals and echocardiogram videos ^{9,13,16}, LVH-fusion jointly 81 82 models both electrocardiogram and echocardiogram data. It is trained not with proximate human derived 83 ECG and echocardiogram labels but rather via a gold standard diagnosis independently derived from the 84 Electronic Health Records (HTN) or through the consensus diagnosis of HCM within a center of 85 excellence.

86 In this study, both single-modal and multimodal neural network models were examined (Figure 1). Four

87 different multimodal fusion architectures were explored, combining ECG and echocardiogram

88 information in different ways. For both late-average fusion and late-ranked fusion models, decision level

fusion was used to combine the outputs of electrocardiogram and echocardiogram classifiers¹⁷. In the late-89 90 average fusion model, soft voting is performed by computing the average probability for each class from 91 the individual ECG and echocardiogram classifiers and predicts the class with maximal average 92 probability. In the late-ranked fusion model, the probabilities for each class from the individual ECG and 93 echocardiogram classifiers are ranked and a prediction is determined from the highest ranked probability. 94 For the late fusion models, both pre-trained and random, the learned feature representations from each 95 modality were concatenated together before the final classification layer. In this situation the fusion 96 model considers both inputs and during training and the loss is calculated jointly. We explored the 97 benefits of randomly initialized weights and pretrained weights in the late fusion model. Lastly, the single 98 modal models provide a benchmark against which to compare multimodal models that jointly consider the 99 paired electrocardiogram and echocardiogram data, demonstrating the benefit of a combined approach.

100 Data Acquisition and selection

101 With the approval of Stanford Institutional Review Board (IRB), we retrieved electrocardiograms and

102 echocardiograms from patients between 2006 and 2018 at Stanford Medicine (Table 1). The data was split

103 into training, validation, and test sets with no patient overlap between sets. Due to the fact that multiple

104 electrocardiograms and echocardiograms are present within the healthcare system record, we explored

105 various data selection scenarios to understand what selection methods are best suited for this specific task.

106 The quantitative comparison of all data selection used can be found in Supplementary Table S1. The final

107 model was trained using a patient's first ECG and first echocardiogram in the system.

108 Model performance

109 Four multimodal fusion models were explored: late-average, late-ranked, pre-trained late fusion

110 and random late fusion (Figure 1). The performance metrics of each model is detailed in Table 2.

111 The late average model achieved the highest F1-score and specificity rates 0.711 (0.571 - 0.826)

and 0.952 (0.921 - 0.979) respectively on the held-out test set. We conducted experiments to

113 study the performance of single-modal models trained on only ECG and echo to demonstrate the

benefit of multimodal models. The multimodal models outperform single-modal model F1-

scores, which increase from 0.63 to 0.71. Furthermore, the false-discovery rates are significantly

reduced from 0.45 to 0.3. To provide context for these results, we also trained the single-modal

117 models to predict left ventricular etiology using standard quantitative features from the

118 electrocardiogram. This baseline model achieved sensitivity rates of 0.51 for predicting HCM

119 which is considerably lower than LVH-Fusion (Supplementary Table S2). These results show

that the proposed electrocardiogram signals model discover novel characteristics not accounted
for with the quantitative features. Lastly, to examine the discriminatory power of our
methodology, we performed a sensitivity analysis for predicting LVH etiology including the
additional classification task of "normal." In this context, LVH-fusion maintains high
discriminatory power in predicting LVH from normal ECG and echocardiogram videos,
suggesting that false positive rates of hypertension or hypertrophic cardiomyopathy would be
low if the model was extended to this use case (Supplementary Table S3 and S4).

127

128 Understanding model performance

129 In order to improve our understanding of how LVH-Fusion classifies left ventricular etiology, we implemented a series of ablation studies similar to Hughes et al. 2021¹⁸ to determine what 130 131 information models rely on to make predictions. For electrocardiogram single-modal models we 132 examined the impact of varying the number of leads from the standard 12 leads to 8 leads and 133 masking each lead to understand the impact each lead holds for prediction estimates. We find 134 that although no single lead harbors a statistically significant impact on the overall model 135 performance, masking out lead V3 and aVR had the highest negative impact on prediction 136 estimates, Figure 2. Next, since the standard 12 lead ECG contains 8 algebraically independent 137 leads, we considered the impact of masking multiple leads combinations. We observe an overall 138 reduction in classification metrics when masking multiple leads at a time with no significant 139 difference between masking the 4 dependent leads (III, aVL, aVF, aVR) and a random 140 subselection of 4 leads, Supplementary Figure S2. These results suggest our model benefits from 141 the complete 12 lead input and classification metrics are negatively impacted with any 142 nonspecific reduction in leads.

143

For the echocardiogram single-modal model, we examined segmentation, restricting the prediction algorithm to i) only the region around the left ventricle, ii) random single frames, and iii) single end diastolic frames. Restricting the echocardiogram model to the area around the left ventricle caused a decrease in accuracy, showing the model relies on information outside of that region to make classifications. This is interesting given the focus of clinicians on the left ventricle when considering LVH, even despite the fact that hypertension could impact the left

150 atrium by causing restriction and HCM affects all four chambers. Restricting the model's input

151 to a single frame further decreases accuracy, demonstrating that motion information is important

- 152 in distinguishing between HCM and hypertension. Figure 2 details the performance of each
- ablation experiment.
- 154

155 Model interpretations

156 In order to improve our understanding of how LVH-Fusion classifies left ventricular etiology, we 157 implemented SHAP GradientExplainer, a game theory approach to explain the output of a machine learning algorithm¹⁹. Relating this method to the ECG model, this approach takes the 158 159 prediction of a model and estimates the gradient with respect to each individual timestep for 160 every lead from the input signal. For echocardiogram videos, an analogous methodology applies: 161 the gradient of the model's prediction was calculated with respect to every pixel from the input 162 video. In each case, the calculated value is then compared to a provided background distribution, 163 the training data. The value of the calculated gradients for each timestep/pixel is then assigned an 164 importance score such that highly impactful scores (denoted in red) hold positive impacts on 165 prediction estimates. Values with low importance scores negatively influence prediction 166 estimates (denoted in blue).

167

168 We emphasize samples of ECG and echocardiograms from the test partition to deduce regions 169 the model found most impactful to prediction estimates, Figure 3 and 4. In Figure 3, the ECG 170 interpretation results highlight an overall focus on V3 and T-wave inversion in leads V1-V6. 171 Both the observed early R wave progression and T-wave inversion are indications of HCM. 172 Summarized local interpretations for each lead provides explanations of the overall impact each 173 lead has on prediction estimates. Additional examples of ECG interpretation tracings can be 174 found in the Supplement Figure S1. Comparably, the interpretation results of the echocardiogram 175 videos, Figure 4, clearly depicts asymmetric proximal septal thickness, a hallmark distinction of 176 HCM across all frames of the video. Next, to examine local summary interpretations, we 177 segmented the left ventricle on each frame for duration of a video's length. This allowed us to 178 quantitatively compare the positive and negative impacts the estimated LV size had on overall 179 prediction estimates, Supplemental Figure S3.

180

181 To further examine if the regions of importance identified in distinct samples are globally similar

across all predictions, a summation or averaging across all local instances was performed. This

183 approach provides a highly compressed, global insight into the model's behavior. We considered

184 per lead contributions to predictions in ECGs and left ventricular segmentation in

185 echocardiogram videos. Global summary results for ECG corroborates our results from the

ablation studies, lead V3 and aVR holds valuable information for model's prediction estimates,

187 Supplement Figure S4.

188 Comparison against physician interpretation

189 We had two expert readers review ECG tracings and echocardiogram videos and asked them to

190 make a diagnosis of HTN or HCM. We selected 45 samples (40 HTN and 5 HCM) from the test

191 set to compare LVH-fusion. The LVH-fusion model outperformed these expert cardiologists

192 (one of whom has 20 years of experience in diagnosing HCM). LVH-fusion correctly classified 3

193 out of the 5 ECG and echocardiogram HCM samples. Variability between cardiologists varied

194 greatly, with one cardiologist matching LVH-fusion sensitivity estimates but with a reduction in

specificity, while cardiologist two failed to correctly classify any of the HCM ECG samples

196 provided.

197 Discussion

198 In this study, we report the first multimodal (ECG and echocardiogram based) deep learning

199 model in clinical cardiology and use it to predict the etiology of left ventricular hypertrophy.

200 Combining complementary knowledge from multiple modalities can improve diagnostic

201 performance in clinical practice. The trained model demonstrates high discriminatory ability in

202 distinguishing hypertrophic cardiomyopathy from hypertension with an AUC of 0.91, AUPRC of

203 0.78. Furthermore, ablation studies provided independent support from unsupervised analysis for

204 clinicians' focus on ECG lateral repolarization and echocardiographic proximal septal

205 hypertrophy for the diagnosis of HCM. Combining complementary information from multiple

206 modalities is intuitively appealing for improving the performance of learning-based approaches.

207 Our results can be directly applied in general medical and cardiology clinics where exposure to

208 rare conditions such as HCM limits confidence in human diagnostic prediction alone.

209

210 Deep learning models specifically focused on single modalities in cardiology have shown impressive results for arrhythmia detection, age, and other clinical actionable insights ^{8,10,16}. 211 212 Previously Ko et al., focused on using convolutional neural networks (CNN) for ECG interpretation with respect to HCM²². They showed high discriminatory power in classifying 213 214 HCM against a background population of left ventricular hypertrophy by ECG alone. However, 215 approximately 28-30% of HCM cases had concurrent hypertension, inhibiting a direct 216 comparison of possible distinction between HCM and hypertension. To date, deep learning 217 research addressing non-pulmonary hypertension detection using electrocardiogram or 218 echocardiogram was unknown. One previous approach successfully used both ECG and 219 echocardiogram data individually with a stepwise approach to diagnosis of cardiac 220 amyloidosis¹⁵, whereas here we focus on fusion method applications of multi-modal deep 221 learning of electrocardiograms and echocardiograms together. 222 223 Medical decision making is complex, often relying on a combination of physician's judgment,

224 experience, diagnostic and screening test results, and longitudinal follow-up. In the case of a 225 patient presenting with anything other than severe, grossly asymmetric LVH, suspicion for HCM 226 would be higher for patients who do not obviously have hypertension. However, occult 227 hypertension is common and challenging to rule out and with mild "gray zone" hypertrophy, it is 228 not uncommon to make this assumption. Similarly, for patients who present with LVH and 229 manifest hypertension, the question is always "is hypertension alone enough to explain this 230 degree of LVH?" Given the implications of missing a diagnosis of HCM—a mendelian disease 231 associated with heart failure and sudden death-most generalists do not feel confident ignoring 232 the possibility of HCM. In these cases, aggressively treating hypertension and re-reviewing the 233 patient can help but challenges in follow up, adherence, and effectiveness of therapy make the 234 window of equipoise long. These are the clinical scenarios into which LVH-fusion will have the 235 most benefit. Yet, this is merely the first application of the approach. A similar approach to the 236 identification of other causes of LVH such as Fabry disease or cardiac amyloidosis can be 237 applied using similar "gold standard" diagnostic labels to those we use here. The future of deep 238 learning in medicine is a move beyond reproducing human derived label features to capitalizing

- on unsupervised machine learned features vs a gold standard diagnostic or prognostic label. This
 will allow machine augmentation of the human led diagnostic journey.
- 241

In summary, we develop a deep learning model incorporating ECG and echocardiogram time series data and apply it to help identify hypertrophic cardiomyopathy patients from within the much larger group of patients presenting with LVH due to hypertension or unknown causes. We present various well known fusion methods of combining data streams from multiple modalities and compare these comprehensively to single-modal models. Further studies should explore the real-world application of physician augmentation approaches like LVH-fusion in medical practice.

249 Methods

250 Data acquisition and study population

- 251 Hypertrophic cardiomyopathy patients were selected for this study from the Hypertrophic
- 252 Cardiomyopathy clinics at the Stanford Center for Inherited Cardiovascular Disease.
- 253 Hypertension patients were selected from individuals that were found to be persistently
- hypertensive (SBP >150) with at least 5 consecutive systolic blood pressure readings over 150.
- 255 Exclusion criteria included any ECG clinical annotations of ventricular-pacing or left bundle
- branch block. In addition, we excluded any data from both electrocardiograms and
- 257 echocardiograms datasets if the date acquired was after a documented myectomy procedure.
- 258
- 259 We retrieved 15,761 electrocardiograms (ECGs) and 3,234 transthoracic echocardiograms from
- 260 2,728 unique individuals at Stanford Health Care, Table 1. Standard 12 lead ECGs were divided
- 261 into training, validation, and test partitions based on a unique patient identification number to
- ensure that no patient overlap existed across data partitions. Echocardiogram videos from
- 263 Stanford Medicine were curated for apical 4-chamber view videos.
- 264 Data Processing and selection
- 265 Electrocardiogram signals were filtered to remove any baseline wander and powerline
- 266 interference. Normalization of 12 lead ECGs was performed by lead over a random subset of the

study sample population, using mean and standard deviation. Echocardiogram videos were

- 268 processed in an identical method as Oyuang et al^{13} . Given multiple electrocardiograms and
- 269 echocardiograms per individual present within our dataset, we examined the effects of different
- 270 data selection methods on model training and performance metrics. We selected three different
- data selection methods: 1) first clinical presentation for all data partitions, 2) all clinical
- 272 presentations in the training partition with only first clinical presentation selected for the
- validation and test partitions, and 3) all clinical presentations for all partitions. Extended details
- of each selection method can be found in Supplemental Table 1.
- 275 Overview of model training framework
- 276 Training for the single-modal and multimodal neural network models were executed
- independently.
- 278 Models were trained using a two-stage grid search approach to find the optimal hyperparameters.
- 279 In the initial hyperparameter search, evaluation metrics from the validation set can be found in
- the Supplementary Tables S5, S6. The hyperparameters that yielded the best performing models
- 281 were selected for additional training and hyperparameter search considering various loss
- 282 functions, loss weighting for minority class and minority class oversampling. Final models were
- 283 selected from the lowest validation loss.
- 284 Single-modal model training
- 285 For electrocardiogram single-modal model training, the following hyperparameters included:
- 286 model architecture: {VGG11, VGG13, VGG16, VGG19, densenet169, densenet121,
- densenet201, densenet161 resnet18, resnet34, resnet50, resnet101, resnet152, resnext50_32x4d,
- resnext101_32x8d, wide_resnet50_2 wide_resnet101_2}; batch size: {32, 64, 75}; Optimizer:
- 289 {SGD, adam}, and Hz: {500, 250}. The first hyperparameter search involved training all
- 290 combinations of hyperparameters above for 100 epochs and saving results from the epoch with
- the lowest loss. Furthermore, we explored a second hyperparameter search which explored class
- 292 weighted loss functions, oversampling minority class samples and setting final bias term to the
- 293 expected class ratios from top performing models from the initial hyperparameters search. We
- 294 examined expanding training to 150 epochs and considering both loss and auPRC results for
- selection of the final model. The selected hyperparameters that resulted in best performance on

the validation set were the following: resnet 34 model, oversampling minority class, adam optimizer,batch size of 64, and sampling rate of 500.

298

299 For echocardiogram unimodal model training, the following hyperparameters included: Model 300 architecture: {r2plus1d_18, mc3_18, r3d_18}, Number of frames: {96, 64, 32, 16, 8, 4, 1}; 301 Period: {2, 4}; Pretrained weights: {True, False}. The first hyperparameter search involved 302 training all combinations of hyperparameters above for 100 epochs and saving results from the 303 epoch with the lowest loss. Furthermore, we explored a second hyperparameter search which 304 explored class weighted loss functions, oversampling minority class samples and setting final 305 bias term to the expected class ratios from top performing models from the initial 306 hyperparameters search. We examined expanding training to 300 epochs and considering both 307 loss and auPRC results for selection of the final model. The selected hyperparameters that 308 resulted in best performance on the validation set were the following: r2plus1d 18 model, 309 pretrained weights, weighted minority class, adam optimizer, batch size of 20, and frames 16 with sampling

310 period of 4.

311 Multimodal model training

312 For multimodal training models, the electrocardiogram and echocardiogram data were paired 313 according to unique patient identifiers. Data selection for the earliest clinical encounter was 314 selected for all training, validation and test set partitions; this resulted in a total of 1,414 training, 315 176 validation, and 168 internal test samples. The detailed characteristics of the dataset can be 316 found in Table 1. We hypothesized that using the learned weights from the single-modal models 317 would benefit training so we explored both pre-trained late fusion and random late fusion 318 models. All multimodal models were trained to 300 epochs and we considered both loss and 319 auPRC results for selection of the final multimodal model. We implemented LVH-Fusion using 320 PyTorch on the Stanford University Research cluster, Sherlock. The selected hyperparameters 321 that resulted in best performance on the validation set were the following: r2plus1d_18 model + 322 resnet 34, pretrained weights, weighted minority class, adam optimizer, batch size of 10, and 323 frames 16 with sampling period of 4.

324 Comparison to feature based models

325 Standard reported features from Tracemaster electrocardiogram machines were extracted for

- 326 each ECG considered in this study. We used these features for input into a XGboost model to
- 327 determine if a feature-based method would exceed the performance metrics of the unimodal
- 328 neural network models. The list of ECG features used were modeled from Kwon et al. 2020^{10} .
- 329 Comparison with normal samples
- 330 In order to explore how our neural networks, perform on non-left ventricular hypertrophy
- individuals, we sampled electrocardiograms with clinical annotations of sinus rhythm and
- echocardiograms with a normal ejection fraction greater than 45. We took the best performing
- 333 single-modal model and retrained them to include an additional non-LVH class; details of
- sample size and performance metrics can be found in Supplementary Table 5 and Supplementary
- 335 Table 6, respectively.
- 336 Ablation experiments
- 337 To further understand how the neural networks make their predictions, we explored various338 ablation studies.
- 339 We retrained the single-modal echo model with data ablated in the following ways:
- 340 1) a single randomly selected frame of each echo, repeated for the length of the original
 341 video to compare to the best performing unimodal model.
- 342 2) The end diastolic frame from each echo, repeated for the length of the original video to
 343 fairly compare to the best performing unimodal model. The end diastolic frame was
 344 identified by a trained sonographer from EchoNet-dynamic¹³.
- 345 3) Using the estimated left ventricular segmentation from EchoNet-dynamic¹³, we set all
 346 pixels to zero except a segmented box around the left ventricle.
- 347 For electrocardiogram we retrained the single-modal models for the following experiments:
- 348 1) Using 8 of the 12 leads, to compare to the best performing unimodal model.
- 349 2) Masking out each lead independently to compare to the best performing single-modal
 350 model and understand impacts each lead holds on performance.
- 351 Echocardiogram models were trained to 300 epochs and electrocardiogram models were trained
- 352 for 150 epochs.

353 SHAP Interpretation experiments

SHAP GradientExplainer¹⁹ uses an extension of integrated gradient values and SHAP values, 354 355 which aims to attribute an importance value to each input feature by integrating the gradients of 356 all interpolations between a foreground sample (test samples) and a provided background 357 samples (training data). The importance scores sum up to approximately the difference between 358 the expected value of all background samples and the individual prediction estimate of interest. 359 We applied this method to both ECG and echocardiogram models; 1500 samples were used to 360 build the background distribution for the ECG model and 80 samples were used to build the 361 background distribution for the echocardiogram model. In both cases, the full test set was used as 362 foreground samples.

363

364 Data and Code availability

All the code for LVH-Fusion will be available at <u>https://github.com/AshleyLab/lvh-fusion/</u> after

366 publication. The data that support the findings of this study are available on request from the

367 corresponding author upon approval of data sharing committees of the respective institutions.

368

369

370 References

Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence
 of hypertrophic cardiomyopathy. *J. Am. Coll. Cardiol.* 65, 1249–1254 (2015).

2. Ho, C. Y. et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy:

374 Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation* **138**,

375 1387–1398 (2018).

376 3. Whelton, P. K. et al. 2017

377 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the

378	Prevention.	Detection.	Evaluation.	and Management	of High	Blood Pr	essure in Adult	s: A
010	1 10 / 01101011	Deceetion	Lindiduli	and management	OI IIIGII	D1000 II		

379 Report of the American College of Cardiology/American Heart Association Task Force on

380 Clinical Practice Guidelines. *Hypertension* **71**, e13–e115 (2018).

- 381 4. Magnusson, P., Palm, A., Branden, E. & Mörner, S. Misclassification of hypertrophic
- 382 cardiomyopathy: validation of diagnostic codes. *Clin. Epidemiol.* **9**, 403–410 (2017).
- 5. Esteva, A. et al. Deep learning-enabled medical computer vision. NPJ Digit Med 4, 5
- 384 (2021).
- 385 6. Pennacchini, E., Musumeci, M. B., Fierro, S., Francia, P. & Autore, C. Distinguishing
- 386 hypertension from hypertrophic cardiomyopathy as a cause of left ventricular hypertrophy.
- 387 J. Clin. Hypertens. 17, 239–241 (2015).
- 388 7. Doi, Y. L. *et al.* Echocardiographic differentiation of hypertensive heart disease and
 389 hypertrophic cardiomyopathy. *Br. Heart J.* 44, 395–400 (1980).
- 390 8. Attia, Z. I. et al. Age and Sex Estimation Using Artificial Intelligence From Standard 12-
- 391 Lead ECGs. *Circ. Arrhythm. Electrophysiol.* **12**, e007284 (2019).
- 392 9. Hannun, A. Y. et al. Cardiologist-level arrhythmia detection and classification in
- ambulatory electrocardiograms using a deep neural network. *Nat. Med.* **25**, 65–69 (2019).
- 10. Kwon, J.-M. *et al.* A deep learning algorithm to detect anaemia with ECGs: a retrospective,
- 395 multicentre study. *Lancet Digit Health* **2**, e358–e367 (2020).
- 396 11. Yao, X. et al. Artificial intelligence–enabled electrocardiograms for identification of
- 397 patients with low ejection fraction: a pragmatic, randomized clinical trial. *Nature Medicine*
- 398 (2021) doi:10.1038/s41591-021-01335-4.
- 399 12. Madani, A., Ong, J. R., Tibrewal, A. & Mofrad, M. R. K. Deep echocardiography: data-
- 400 efficient supervised and semi-supervised deep learning towards automated diagnosis of

- 401 cardiac disease. *NPJ Digit Med* **1**, 59 (2018).
- 402 13. Ouyang, D. *et al.* Video-based AI for beat-to-beat assessment of cardiac function. *Nature*403 580, 252–256 (2020).
- 404 14. Huang, S.-C., Pareek, A., Zamanian, R., Banerjee, I. & Lungren, M. P. Multimodal fusion
- 405 with deep neural networks for leveraging CT imaging and electronic health record: a case-
- 406 study in pulmonary embolism detection. *Sci. Rep.* **10**, 22147 (2020).
- 407 15. Goto, S. et al. Artificial intelligence-enabled fully automated detection of cardiac
- 408 amyloidosis using electrocardiograms and echocardiograms. *Nat. Commun.* **12**, 2726 (2021).
- 409 16. Attia, Z. I. *et al.* An artificial intelligence-enabled ECG algorithm for the identification of
- 410 patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome
- 411 prediction. *Lancet* **394**, 861–867 (2019).
- 412 17. Sagi, O. & Rokach, L. Ensemble learning: A survey. Wiley Interdiscip. Rev. Data Min.
- 413 *Knowl. Discov.* **8**, e1249 (2018).
- 414 18. Hughes, J. W. *et al.* Deep learning prediction of biomarkers from echocardiogram videos.
- 415 *bioRxiv* (2021) doi:10.1101/2021.02.03.21251080.
- 416 19. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. *arXiv*417 [*cs.LG*] (2017).
- 418 20. Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a
- 419 meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 360,
 420 1903–1913 (2002).
- 421 21. Parato, V. M. *et al.* Echocardiographic diagnosis of the different phenotypes of hypertrophic
 422 cardiomyopathy. *Cardiovasc. Ultrasound* 14, 30 (2016).
- 423 22. Ko, W.-Y. *et al.* Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural

424 Network-Enabled Electrocardiogram. J. Am. Coll. Cardiol. 75, 722–733 (2020).

- 426
- 427

428 FIGURES

429

430 Figure 1. LVH-Fusion study design.

- 431 Two disease of interested are denoted, HCM and HTN, alongside data modality types used in
- this study. Single modal as well as multimodal model architecture were explored. LVH-Fusion is
- 433 based on a late average fusion neural network, denoted in blue.
- 434



439 Figure 2, Ablation studies impact on LVH-Fusion performance

440 Bootstrap 95% CI for performance metrics, F1-score and average precision score, for each model

- 441 trained on ablated input data. for each prediction metric is shown. (TOP row) Results from
- 442 ablating ECG input. (BOTTOM row) Results from ablating echocardiogram input. For each
- 443 ablation setting, a separate model was trained on that type of ablated data to quantify the
- 444 information content in the data.
- 445



446 447

449 Figure 3, LVH-Fusion ECG interpretations.

- 450 SHAP explanations of one true positive, HCM sample (A). Red areas indicate timesteps that hold 451 a positive impact on prediction, while blue timesteps indicate a negative impact on prediction, no
- 452 color is neutral. (B) Selected regions of ECG leads denote timesteps of high estimated
- 453 importance, focusing on inverted T-waves and lead V3 R peaks. (C) Local explanations of the
- 454 cumulative SHAP values on prediction output across leads. Lead V3 overall contains the highest
- 455 values of SHAP values for this sample presented.
- 456
- 457



460 **Figure 4, LVH-Fusion echocardiogram interpretations.**

461 SHAP explanations for two true positive samples, HCM (top row) and HTN (bottom row). Each

462 class has 3 frames selected with SHAP values overlaid. Red areas indicate pixels that hold a

463 positive impact on prediction, while blue pixels indicate a negative impact on prediction, no

464 color is neutral. We observe red areas of importance converging on the asymmetric septal wall in

the HCM example.

466



467 468 469

470471 TABLES

472

Table 1 Breakdown of data by partition

Label	Partition	Number of unique Echo patients	Number of Echos	Number of unique ECG patients	Number of ECGs
	Train	256	596	662	4,281
HCM	Validate	31	58	71	424
	Test	27	88	78	380
	Train	1,469	1,976	1,535	8,348
HTN	Validate	186	270	191	1,127
	Test	181	246	191	1,201

Models	auROC	auPRC	F1-score	Sensitivity	Specificity	Precision	NPV	FPR	FNR	FDR
Late averaged fusion	0.914 (0.858 -	0.781 (0.642 -	0.711 (0.571 -	0.727 (0.560 -	0.952 (0.921 -	0.696 (0.526 -	0.959 (0.930 -	0.048 (0.021 -	0.273 (0.118 -	0.304 (0.148
	0.961)	0.898)	0.826)	0.880)	0.979)	0.850)	0.986)	0.078)	0.438)	0.467)
Late ranked fusion	0.917 (0.866 -	0.758 (0.621 -	0.480 (0.353 -	0.818 (0.667 -	0.760 (0.701 -	0.340 (0.235 -	0.965 (0.935 -	0.240 (0.182 -	0.182 (0.050 -	0.660 (0.552
	0.960)	0.874)	0.591)	0.950)	0.818)	0.449)	0.991)	0.299)	0.333)	0.766)
Late fusion random	0.890 (0.832 -	0.643 (0.475 -	0.556 (0.409 -	0.682 (0.500 -	0.884 (0.838 -	0.469 (0.323 -	0.949 (0.915 -	0.116 (0.075 -	0.318 (0.156 -	0.531 (0.382
	0.941)	0.803)	0.681)	0.842)	0.925)	0.621)	0.978)	0.162)	0.500)	0.679)
Late fusion pretrained	0.891 (0.829 -	0.625 (0.460 -	0.452 (0.333 -	0.864 (0.731 -	0.705 (0.642 -	0.306 (0.210 -	0.972 (0.943 -	0.295 (0.234 -	0.136 (0.033 -	0.694 (0.596
	0.943)	0.784)	0.556)	0.967)	0.767)	0.403)	1.000)	0.359)	0.269)	0.787)
Single modal: ECG	0.834 (0.784 -	0.686 (0.590 -	0.639 (0.555 -	0.676 (0.580 -	0.831 (0.786 -	0.605 (0.512 -	0.871 (0.828 -	0.169 (0.123 -	0.324 (0.231 -	0.395 (0.304
	0.880)	0.776)	0.712)	0.770)	0.877)	0.696)	0.912)	0.216)	0.418)	0.488)
Single modal:	0.889 (0.828 -	0.719 (0.588 -	0.625 (0.500 -	0.741 (0.591 -	0.906 (0.870 -	0.541 (0.406 -	0.959 (0.932 -	0.094 (0.060 -	0.259 (0.125 -	0.459 (0.324
Echocardiogram	0.942)	0.833)	0.735)	0.875)	0.940)	0.676)	0.982)	0.130)	0.407)	0.595)

Table 2: Model performance metrics

477 SUPPLEMENTAL TABLES AND FIGURES

478

479

Supplemental Table S1

Data Selection Label		Number of unique Echo patients	Number of Echos	Number of unique ECG patients	Number of ECGs
First Encounters, train, val, and test	HCM				
		314	314	811	811
	HTN				
		1,836	1,836	1,917	1,917
First Encounter, val and test	HCM				
		314	654	811	4,430
	HTN				
		1,836	2,343	1,917	8,730
All Encounters train, val, and test	HCM				
		324	763	917	6,027
	HTN				
		1,848	2,516	1,977	13,045

482

-

Supplemental Table S2

Model	Loss	auPRC	Optim	Batch	Data Selection
VGG11	0.502	0.591	adam	75	First Encounters, all
VGG13	0.448	0.672	adam	64	First Encounters, all
VGG16	0.493	0.559	adam	64	First Encounters, all
VGG19	0.501	0.559	adam	64	First Encounters, all
densenet121	0.395	0.738	adam	64	First Encounters, all
densenet161	0.449	0.639	adam	64	First Encounters, all
densenet169	0.41	0.722	adam	75	First Encounters, val and test only
densenet201	0.433	0.724	adam	64	First Encounters, all
resnet101	0.427	0.702	adam	75	First Encounters, all
resnet152	0.434	0.715	adam	64	First Encounters, all
resnet18	0.405	0.727	adam	64	First Encounters, all
resnet34	0.383	0.781	adam	64	First Encounters, all
resnet50	0.429	0.73	adam	75	First Encounters, all
resnext101_32x8d	0.405	0.741	adam	75	First Encounters, all
resnext50_32x4d	0.405	0.734	adam	64	First Encounters, all
wide_resnet101_2	0.426	0.69	adam	75	First Encounters, all
wide_resnet50_2	0.416	0.692	adam	64	First Encounters, all

485

Supplemental Table S3

Model	loss	auPRC	optim	frames	period	File selection
mc3	0.134	0.893	adam	16	2	First Encounters, all
r2plus1d	0.171	0.851	adam	16	4	First Encounters, all
r3d	0.152	0.879	adam	16	4	First Encounters, all

486

Supplemental Table S4

	auROC	auPRC	F1score	Sensitivity	Specificity	PPV	NPV	FPR	FNR	FDR
Reduced features (11)										
	0.71	0.59	0.5	0.43	0.89	0.6	0.8	0.11	0.57	0.4
Large features (468)										
	0.84	0.73	0.59	0.47	0.95	0.78	0.82	0.05	0.53	0.22

487

Supplemental Table S5

	f1-score	precision	recall	support
HTN				
	0.71	0.78	0.65	181
НСМ				
	0.41	1.00	0.26	27
NORMAL EF				
	0.95	0.92	0.97	876
illaci o avg	0.69	0.90	0.63	1084
weighted avg	0.00	0.00	0.00	1004
	0.89	0.90	0.90	1084

Supplemental Table S6

	f1-score	precision	recall	support
HTN	0.20	0.25	0.44	170
нсм	0.39	0.35	0.44	178
нсм	0.36	0.26	0.57	68
SINUS				
	0.91	0.95	0.88	1789
macro avg	0.56	0.52	0.63	2035
weighted avg				
_ 0	0.85	0.87	0.83	2035

496 497

498 499 Supplemental Figure S1, Additional examples of true positive HCM ECGs 499



 $\begin{array}{c} 500 \\ 501 \end{array}$

502 Supplemental Figure S2, ECG ablation study of multiple lead masking



503 504

Supplemental Figure S3, Echo SHAP local feature importance plot



508 Supplemental Figure S4, ECG SHAP global feature importance plot

- 509 The global importance of each lead is taken to be the mean absolute value summation for each
- 510 lead over all the given samples. Hypertension (HTN) is in solid red, Hypertrophic
- 511 Cardiomyopathy (HCM) is denoted by stripes. Lead V3 is ranks highest overall in global feature
- 512 importance.
- 513

